Controlled Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites in Tanzanian Adults

Inclusion Criteria: * Healthy Male aged between 20-35 years, healthy volunteers * Good Health status based on history \& clinical examination * Residing in or near DaresSalaam * Willing to contribute to science in Tanzania * Free from malaria parasite by blood smear \& qRT-PCR * Not suffering from any chronic illness including HIV/AIDS * No documented history of malaria infection for the past 5 yrs * Able \& willing to come for complete one year follow up including minimum of three weeks of hospitalization * All volunteers must sign the informed consent form \& answer correctly 15 out 15 questions demonstrating their understanding of the meaning \& procedures of the study * Volunteer agrees to inform study doctor \& agrees to release medical information concerning contra-indications for participation in the study * Living with a third party that will contact the study team if in case of alteration of consciousness during the first month of the study * Willing to undergo a Pf sporozoite challenge. * Willing to take curative treatment for malaria (Coartem®) \& any other medication which may be prescribed by a study doctor during study period * All volunteers agree to stay in the hospital during parts of the study (overnight after challenge, up to 15 days during follow up \& 3 days of Coartem® treatment) * Reachable (24/7) by mobile phone during the whole study period * Agreement not to participate in another study during the study period. * Agreement not to donate blood during the study period. * Available to attend all study visits * Willingness to undergo HIV, hepatitis B \& hepatitis C tests Exclusion Criteria: * History of malaria in the past 5 yrs * Plans to travel outside the Dar-es-salaam or Coast Region in first month (day 0-28) of the study * Plans to travel to highly malarious areas in the 6 months following the study period * Previous participation in malaria vaccine study \&/or positive serology for Plasmodium falciparum asexual crude extract antibodies above acceptable cut off established for the site. * History of arrhythmias or prolonged QT-interval or other cardiac disease * Positive family history of in the 1st \& 2nd degree relative for cardiac disease \<50 yrs old. * Volunteers unable to read \& write in English \& give written informed consent * Previous history of drug or alcohol abuse interfering with normal social function * A history of psychiatric disease * The use of chronic immunosuppressive drugs, antibiotics, or other immune modifying drugs within three months of study onset (inhaled \& topical corticosteroids are allowed) \& during the study period * A history or confirmed sickle cell anemia, sickle cell trait, thalassemia , thalassemia trait or G6PD deficiency * Co-worker of the Ifakara Health Institute * Symptoms, physical signs \& laboratory values suggestive of systemic disorders including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric, \& other conditions which could interfere with the interpretation of the study results or compromise the health of the volunteers * History of diabetes mellitus or cancer * An estimated, ten year risk of fatal cardiovascular disease of \<5%, as estimated by the Systematic Coronary Risk Evaluation (SCORE) system * Clinically significant abnormalities in electrocardiogram at screening * Body Mass Index below 18 or above 30kg/m2 * Any clinically significant deviation from the normal range in biochemistry or hematology blood tests or in urine analysis or electrolytes * Positive HIV, Hepatitis B virus or Hepatitis C Virus tests * Participation in any other clinical study within 30 days prior to the onset of the study or during the study period * Volunteers unable to be closely followed for social, geographic or psychological reasons * Known hypersensitivity of other contra-indications to Coaterm® or Malarone® including treatment taken by the volunteer that interferes with Coartem® or Malarone® * Any confirmed or suspected immunosuppressive or immunodeficient condition, including asplenia